Ashkan Rezazadeh Ardabili,Zlatan Mujagić,Manasi Agrawal et al.
Ashkan Rezazadeh Ardabili et al.
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus [0.03%]
药物治疗非肝硬化代谢紊乱相关steatohepatitis：英国专家共识
Jeremy F Cobbold,Hamish Miller,Kate Hallsworth et al.
Jeremy F Cobbold et al.
Metabolic dysfunction-associated steatohepatitis (MASH), a potentially progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), increases risk of fibrosis progression, cirrhosis, and liver-related and cardiometa...
Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trial [0.03%]
关于错配修复缺陷型直肠癌患者使用纳武单抗和伊匹木单抗双免疗法一个或两个疗程的疗效：RESET-R研究中期结果（一项多中心、单组、Ⅱ期临床试验）
Line Schmidt Tarpgaard,Laurids Østergaard Poulsen,Ismail Gögenur et al.
Line Schmidt Tarpgaard et al.
Background: Mismatch repair-deficient (dMMR) tumours are highly sensitive to immune checkpoint blockade in the metastatic setting. Previous trials showed near-universal pathological responses after short-course dual immun...
Rifaximin in cirrhosis: when therapeutic drift meets antimicrobial stewardship [0.03%]
利福昔明在肝硬化治疗中的应用：当治疗理念的演变遇到抗菌药物管理
Rajiv Jalan,Vishal C Patel,Saeed Shoaie
Rajiv Jalan
This Viewpoint examines the evolving role of rifaximin in cirrhosis, arguing that therapeutic drift has outpaced evidence and antimicrobial stewardship. While rifaximin is effective for secondary prevention of recurrent overt hepatic enceph...
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 [0.03%]
代谢紊乱相关肝脂肪变性肝病的全球疾病负担（1990年至2023年）及2050年前预测：基于全球疾病负担研究2023年的系统分析
GBD MASLD Collaborators
GBD MASLD Collaborators
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is one of the most prevalent liver diseases globally, contributing to both economic and ...
André is an Idiot [0.03%]
安德烈是个白痴
Joe Moody
Joe Moody
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial [0.03%]
机器人辅助与传统微创食管切除术治疗食管鳞状细胞癌（RAMIE）：一项多中心、开放性、随机、III期非劣效性试验
Yang Yang,Zhichao Liu,Chunguang Li et al.
Yang Yang et al.
Background: Robot-assisted minimally invasive oesophagectomy is used increasingly worldwide. However, no large-scale, multicentre, randomised controlled trial has compared long-term survival as the primary endpoint betwee...